ClinicalTrials.gg
CompletedNCT06962735Updated May 11, 2025

Real-world Effect of Switching From Intermittently-scanned to Real-time Continuous Glucose Monitoring (Switch CGM Retro)

An observational study in Diabetes Mellitus, sponsored by LMC Diabetes & Endocrinology Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by LMC Diabetes & Endocrinology Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
220
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 493 studies in Diabetes Mellitus with a site in Canada — 39 open to participants now, 55 under way, 5 of them phase 3. Diabetes Mellitus · Canada.

Enrollment
36th of 92
220 · median 100
Started
2024
with 13 others
Observational
92 of 493
14 open now
Registered
475th of 493
by date

Among the 493 studies in Diabetes Mellitus with a site in Canada, this one is the 36th largest by enrollment of the 92 observational ones that give a count, is one of 14 that started in 2024, is one of 92 observational ones, and was the 475th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

39 of the 493 studies in Diabetes Mellitus with a site in Canada are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 493 studies in Diabetes Mellitus with a site in Canada, or all of them as a file.
02

Study summary

The objective of this retrospective, observational study, is to better understand the real-world glycemic effectiveness of switching to real time continuous glucose monitoring (rtCGM) from intermittently scanned continuous glucose monitoring (isCGM) among adults with type 1 diabetes or type 2 diabetes in Canada.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adults, who were active patients with type 1 diabetes or type 2 diabetes at LMC, who switched from intermittently scanned continuous glucose monitoring to real-time continuous glucose monitoring (rtCGM switch cohort) or initiated and maintained intermittently scanned continuous glucose monitoring use (isCGM cohort).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older as of the index date
  • Clinical diagnosis of T1D or T2D ≥ one year
  • Using either MDI or CSII therapy
  • Initiated a FreeStyle Libre® isCGM device between January 1, 2018 and July 31, 2023 (isCGM cohort)
  • Switched from a FreeStyle Libre® 1 or Libre 2® isCGM device to a Dexcom® G5 or G6 CGM device between April 1, 2018 and July 31, 2023 (rtCGM cohort)
  • Baseline ≥7.0% for primary objective with rtCGM cohort
  • Baseline HbA1c ≥8.0% for key secondary objective comparing rtCGM cohort to isCGM cohort
  • Known rtCGM/isCGM start date (month and year)
  • Exclusive use of isCGM for ≥ 3 months
  • ≥ one HbA1c value up to 6 months (± 6 weeks) prior to index date (HbA1c value must be after isCGM initiation and no more than 6 weeks after the index date)
  • ≥ one HbA1c value 6-12 months (± 6 weeks) following the index date
  • for their medical record data to be used for research purposes

Exclusion criteria

Exclusion Criteria:

  • Have a prior history of rtCGM within 12 months of the index date
  • Are pregnant at the time of isCGM initiation or time of switch to rtCGM
  • Used the isCGM or rtCGM for \< 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
220 participants (actual)
Patient registry
No

Groups and cohorts

  • real-time continuous glucose monitoring switch group (rtCGM switch group)

    adults with diabetes that switched from an isCGM to an rtCGM

    Device: real-time continuous glucose monitor

  • intermittently scanned continuous glucose monitoring group (isCGM group)

    adults with diabetes that remained on an isCGM

Interventions

  • Devicereal-time continuous glucose monitor

    Individuals who switched from using isCGM to rtCGM

06

What researchers measure

Primary outcomes

  1. Change in HbA1c at 6-12-month follow-up compared to baseline

    To evaluate change in HbA1c at 6-12-month follow-up compared to baseline after switching from an isCGM system to a rtCGM system in adults with type 1 diabetes

    Time frame: from index date to 6- to-12-month follow-up

Secondary outcomes

  1. Change in HbA1c in the rtCGM switch cohort compared to a matched isCGM cohort

    To compare 6-12 month change in HbA1c in the rtCGM switch cohort, who switched from isCGM to rtCGM, compared to a propensity score matched isCGM cohort, who maintained isCGM use, among a subgroup of patients with T1D and HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  2. Change in percent time in target glucose range (TIR) at 6-12 months follow-up

    To evaluate change in percent TIR at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  3. Change in percent time below target glucose range (TBR)

    To evaluate change in percent TBR at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  4. Change in percent time above target glucose range (TAR)

    To evaluate change in percent TAR at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  5. Change in mean glucose

    To evaluate change in mean glucose at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  6. Change in standard deviation (SD) of mean glucose

    To evaluate change in SD of mean glucose at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  7. Change in coefficient of variation (CV) of mean glucose

    To evaluate change in CV of mean glucose at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  8. Change in weight

    To evaluate change in weight at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  9. Proportion of patients who achieve HbA1c ≤7.0%

    To evaluate the proportion of patients who achieve HbA1c ≤7.0% at 6-12 months follow-up in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% at baseline and propensity score matched isCGM cohort with HbA1c ≥ 7.5% at baseline.

    Time frame: evaluated at 6- to-12-month follow-up

  10. Weekly incidence of self-reported hypoglycemia

    To evaluate weekly incidence of self-reported hypoglycemia at 6-12 months in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: evaluated at 6- to-12-month follow-up

  11. Proportion of patients with ≥ 1 self-reported hypoglycemic event

    To evaluate proportion of patients with ≥ 1 self-reported hypoglycemic event at 6-12 months in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: evaluated at 6- to-12-month follow-up

  12. Change in total daily dose (TDD) of insulin

    To evaluate change in TDD of insulin at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.

    Time frame: from index date to 6- to-12-month follow-up

  13. Proportion of patients using a Tandem® insulin pump in the rtCGM switch cohort

    To evaluate proportion of patients using a Tandem® insulin pump in the rtCGM switch cohort during the study period from baseline to 6-12 months follow-up.

    Time frame: from index date to 6- to-12-month follow-up

07

Study locations

1 site
  • LMC Diabetes & Endocrinology Ltd.
    Toronto, Ontario M4G3E8, Canada
08

References and documents

Individual participant data

Plan to share: No — This is a real-world study using data retrieved from a national Diabetes Registry. IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Aug 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
Jan 25, 2024
Primary completionActual
Aug 29, 2024
CompletionActual
Aug 29, 2024
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06962735
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Collaborators
DexCom, Inc.
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Jan 25, 2024
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024
Last update
May 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion